Semaglutide
GLP-1Evidence-based breakdown of weight loss, blood sugar effects, heart benefits, and side effects—so you know what to expect before taking it.
Based on randomized clinical trials and real-world outcomes.
Produces meaningful weight loss (8-12%) and good blood sugar control. Limited long-term durability data.
💊 What This Drug Does
🛡️ Safety Profile
Why This Rating
- Nausea and vomiting are common but usually manageable with gradual dose increase
- No major safety signals from trials, though long-term data only extend to ~3 years
- Most people who tolerate it continue taking it long-term
Safety Breakdown
Common side effects
Nausea occurs in ~25% of people, vomiting in ~6%. Usually improves over weeks but can be bothersome initially.
Serious safety concerns
No major adverse event signals in trials. Rare reports of pancreatitis and gallbladder issues exist but are not common.
How often people stop
About 5–10% of people stop because of nausea or GI problems. Majority who tolerate it persist long-term.
How hard it is to manage
Subcutaneous injection once weekly. Requires gradual dose escalation over ~4 weeks. No routine lab monitoring required.
How certain we are long-term
Modern trials with solid methodology, but longest published follow-up is ~3 years. Safety beyond 5 years is less certain.
Key Safety Flags
- Common nausea, especially when starting—usually improves with slower dose increase
- Pancreatitis and gallbladder concerns warrant monitoring
- Long-term safety data extend only to ~3 years
- Weight typically returns within months if you stop the drug
⚖️ Weight Loss Effects
How strong is this result?
What the Studies Show
Across several randomized trials (including STEP 1 and STEP 2), researchers found 8–12% weight loss for this outcome.
Who participated: Adults with obesity (BMI ≥30), no diabetes; primarily White, middle-aged (45–65 years); structured medical support
How confident are we? Effect size: high – consistent 8–12% effect across step trials | Generalizability: moderate – primarily white, age 45–65, structured medical setting; may not apply to younger, more diverse, or less-supported populations | Durability: limited – longest published data ~2 years; weight regain patterns post-discontinuation unclear | Real-world applicability: moderate – intensive rct support with frequent visits; real-world adherence and dropout likely higher
Study context: Follow-up may be too short to fully assess long-term effects.
📊 Blood Sugar Control (Diabetes)
How strong is this result?
Strong diabetes control effect, comparable to other modern GLP-1 drugs. Can shift patients from uncontrolled to well-controlled, meaningfully reducing complications like kidney disease and blindness.
What the Studies Show
Across several randomized trials (including SUSTAIN 2 and SUSTAIN 3), researchers found −1.5% HbA1c reduction for this outcome.
Who participated: Adults with type 2 diabetes; various stages (treatment-naïve to insulin-requiring); age 40–70; BMI 25–40
How confident are we? High confidence (modern studies)
❤️ Heart Health Effects
How strong is this result?
Clinically meaningful result. A 20% reduction in heart attacks and strokes is significant and ranks among the strongest cardiovascular benefits seen with any obesity or diabetes medication.
What the Studies Show
Across several randomized trials (SUSTAIN 6 and SELECT), researchers found 18–26% MACE reduction for this outcome.
Who participated: SUSTAIN 6: Type 2 diabetes with established CVD or high risk; SELECT: Obesity with established CVD
How confident are we? High confidence (modern studies)
⚠️ What To Keep In Mind
All clinical evidence comes with limitations. Here's what matters for interpreting this drug's data:
- All trials were funded by the drug manufacturer.
- Limited evidence beyond 2 years of use.
- It is unclear whether heart benefits come from weight loss, blood sugar control, or direct effects on the heart.
- Trial participants were primarily middle-aged and White. Results may not apply to younger, more diverse populations.
- Heart health benefits are shown in people with existing heart disease. Results may not apply to people without heart disease.
- Weight loss was measured as a secondary outcome (not the main focus) in these trials.
- Trial participants volunteered knowing the drug being tested. This may have selected for those more likely to tolerate it.
- Heart health benefits are shown in only 2 large trials.